Cargando…

Cooperative effects of Janus and Aurora kinase inhibition by CEP701 in cells expressing Jak2V617F

The Janus kinase 2 mutant V617F occurs with high frequency in myeloproliferative neoplasms. Further mutations affecting the Janus kinase family have been discovered mostly in leukaemias and in myeloproliferative neoplasms. Owing to their involvement in neoplasia, inflammatory diseases and in the imm...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gäbler, Karoline, Rolvering, Catherine, Kaczor, Jakub, Eulenfeld, René, Méndez, Sergio Álvarez, Berchem, Guy, Palissot, Valérie, Behrmann, Iris, Haan, Claude
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2013
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3822589/ https://www.ncbi.nlm.nih.gov/pubmed/23301855 http://dx.doi.org/10.1111/jcmm.12005

Ejemplares similares

JAK2-V617F-induced MAPK activity is regulated by PI3K and acts synergistically with PI3K on the proliferation of JAK2-V617F-positive cells
por: Wolf, Alexandra, et al.
Publicado: (2013)

JAK2 mutants (e.g., JAK2V617F) and their importance as drug targets in myeloproliferative neoplasms
por: Gäbler, Karoline, et al.
Publicado: (2013)

Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases
por: Haan, Claude, et al.
Publicado: (2010)

The Janus kinases (Jaks)
por: Yamaoka, Kunihiro, et al.
Publicado: (2004)

CEP55 promotes cilia disassembly through stabilizing Aurora A kinase
por: Zhang, Yu-Cheng, et al.
Publicado: (2021)

Quantitative assay for the detection of the V617F variant in the Janus kinase 2 (JAK2) gene using the Luminex xMAP technology
por: Paradis, François W, et al.
Publicado: (2010)

Recombinant Interleukin-24 Lacks Apoptosis-Inducing Properties in Melanoma Cells
por: Kreis, Stephanie, et al.
Publicado: (2007)

Janus Kinase V617F Mutation Detection in Patients with Myelofibrosis
por: Nikolova, D, et al.
Publicado: (2019)

Cep63 and Cep152 Cooperate to Ensure Centriole Duplication
por: Brown, Nicola J., et al.
Publicado: (2013)

JAK2V617F-Positive Endothelial Cells Induce Apoptosis and Release JAK2V617F-Positive Microparticles
por: Hekimoğlu, Hilal, et al.
Publicado: (2022)

Time allocation to R 701
por: CERN. Geneva. ISR Experiments Committee
Publicado: (1974)

The oncogenic FIP1L1-PDGFRα fusion protein displays skewed signaling properties compared to its wild-type PDGFRα counterpart
por: Haan, Serge, et al.
Publicado: (2015)

JAK2 inhibitor CEP-33779 prevents mouse oocyte maturation in vitro
por: Wu, Changli, et al.
Publicado: (2017)

Histone Deacetylase 701 (HDT701) Induces Flowering in Rice by Modulating Expression of OsIDS1
por: Cho, Lae-Hyeon, et al.
Publicado: (2018)

The JAK2 V617F mutation in isolated neutropenia
por: Langabeer, Stephen E.
Publicado: (2018)

Megakaryocytic morphology in Janus kinase 2 V617F positive myeloproliferative neoplasm
por: Ghai, Shuchi, et al.
Publicado: (2017)

CEP19 cooperates with FOP and CEP350 to drive early steps in the ciliogenesis programme
por: Mojarad, Bahareh A., et al.
Publicado: (2017)

Prognostic significance of ASXL1, JAK2V617F mutations and JAK2V617F allele burden in Philadelphia-negative myeloproliferative neoplasms
por: Yonal-Hindilerden, Ipek, et al.
Publicado: (2015)

Anti-Glucosylsphingosine Autoimmunity, JAK2V617F-Dependent Interleukin-1β and JAK2V617F-Independent Cytokines in Myeloproliferative Neoplasms
por: Allain-Maillet, Sophie, et al.
Publicado: (2020)

Clinical features and outcomes of JAK2 V617F-positive polycythemia vera and essential thrombocythemia according to the JAK2 V617F allele burden
por: Lee, A-Jin, et al.
Publicado: (2021)

The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective
por: Staerk, Judith, et al.
Publicado: (2012)

JAK2 and Beyond: JAK2V617 Mutational Study of Myeloproliferative Disorders and Haematological Malignancies
por: Syeed, Nidda
Publicado: (2019)

The Janus Kinase (JAK) FERM and SH2 Domains: Bringing Specificity to JAK–Receptor Interactions
por: Ferrao, Ryan, et al.
Publicado: (2017)

Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
por: Blume-Peytavi, Ulrike, et al.
Publicado: (2015)

Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo
por: Abdou, Asmaa Gaber, et al.
Publicado: (2018)

JAK2 V617F and the evolving paradigm of polycythemia vera
por: Means, Robert T.
Publicado: (2010)

Hemochromatosis, Erythrocytosis and the JAK2 p.V617F Mutation
por: Langabeer, Stephen E.
Publicado: (2017)

Absence of JAK2V617F Mutated Endothelial Colony-Forming Cells in Patients With JAK2V617F Myeloproliferative Neoplasms and Splanchnic Vein Thrombosis
por: Guy, Alexandre, et al.
Publicado: (2020)

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING
por: Chary Nimmagadda, Subbaiah, et al.
Publicado: (2023)

Iron deficiency in JAK2 exon12 and JAK2-V617F mutated polycythemia vera
por: Liu, Dan, et al.
Publicado: (2021)

JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden
por: Ferdowsi, Shirin, et al.
Publicado: (2016)

Janus kinase 2 V617F mutation in an unrelated peripheral blood stem cell donor
por: Yang, Shang-Hsien, et al.
Publicado: (2019)

Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients
por: Karim, Sajjad, et al.
Publicado: (2019)

Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
por: Sugimori, C, et al.
Publicado: (2012)

International external quality assurance of JAK2 V617F quantification
por: Asp, Julia, et al.
Publicado: (2018)

The JAK2 V617F mutation in retinal vein or artery occlusion
por: Langabeer, Stephen E.
Publicado: (2019)

Chorea Associated with JAK2(V617F) ‐Positive Essential Thrombocythemia
por: Calculli, Alessandra, et al.
Publicado: (2022)

Enhancing SHP-1 expression with 5-azacytidine may inhibit STAT3 activation and confer sensitivity in lestaurtinib (CEP-701)-resistant FLT3-ITD positive acute myeloid leukemia
por: Al-Jamal, Hamid Ali Nagi, et al.
Publicado: (2015)

Impact of JAK2V617F Mutation Burden on Disease Phenotype in Chinese Patients with JAK2V617F-positive Polycythemia Vera (PV) and Essential thrombocythemia (ET)
por: Zhao, Shixiang, et al.
Publicado: (2016)

JAK out of the box: myeloproliferative neoplasms--associated JAK2 V617F mutations contribute to aortic aneurysms
por: Elf, Shannon E.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_svdn6s5loj3ervjuq7s3vdf9fl